-
How many women in your family planning facility may be missing a needed Pap smear? Check your numbers: One-fourth of uninsured U.S. women between the ages of 18-64 report not having had a Pap smear within the last three years of a government-issued survey.
-
New research released on Lybrel, the first dedicated continuous use oral contraceptive (OC) (Wyeth Pharmaceuticals; Collegeville, PA), underscores the safety of the new drug.
-
If your practice includes older women, what is your approach in discussing risks for HIV? It's time to address such issues. Results of a new study indicate that older women may not be interested in being tested for HIV, despite having significant risk factors for lifetime exposure.
-
Researchers have launched a clinical safety trial of VivaGel (SPL7013), a topical vaginal microbicide, for potential use in preventing the sexual transmission of HIV.
-
Your next patient says she is interested in using Lybrel, the new continuous-use oral contraceptive (OC). What should you tell her about this form of birth control?
-
Your next patient is a young mother of three who is looking for long-term, effective contraception. She says she is not ready to consider tubal sterilization. What methods can you offer her?
-
Patients with peripheral artery disease are at high risk for cardiovascular complications. Antiplatelet drugs are routinely prescribed for these patients, but is adding an oral anticoagulant of value?
-
Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States, causing an estimated 6 million new genital infections annually.
-
-